Aktuellt
SENASTE
Redeye maintains its estimates with minor changes following Nanologica’s Q2 2023 report, on which we have a rather neutral take. Sales should start increasing from Q3 onwards, and we see the potential for an eventful H2 for Nanologica, which trades at a discount to our base case.
LÄS MER
